Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Type 1 Diabetes
Mechanism of Action
Stem Cell-Derived Islets
Clinical Trial
NCT04786262Last updated: 12/3/2025
VRTX
Vertex Pharmaceuticals Incorporated
